Athos + Vultr: Accelerating AI-Driven Drug Discovery
Athos + Vultr: Accelerating AI-Driven Drug Discovery
NVIDIA GPUs on Vultr accelerate Athos's AI, reduce costs, and ensure agile, secure research.
NVIDIA GPUs on Vultr accelerate Athos's AI, reduce costs, and ensure agile, secure research.
Athos Therapeutics sought a cloud solution to accelerate its AI-powered drug discovery for autoimmune diseases and cancer. Legacy clouds proved too costly and inflexible, hindering their ability to rapidly iterate on vast patient datasets.
Vultr, with NVIDIA HGX™ H100 GPUs, provides Athos with a scalable, secure, and cost-effective platform. This empowers Athos to develop next-generation treatments faster while safeguarding valuable intellectual property.
Vultr's cloud GPUs enable faster innovation in biotech research
Vultr's cloud GPUs enable faster innovation in biotech research
Vultr's solution, co-engineered with Dell Technologies, offers Athos agile infrastructure that adapts to evolving research needs. Dedicated engineering support, robust security, and user-friendly management tools eliminate on-premises constraints, allowing Athos to focus on innovation and unlock faster time-to-market.
Get started with
world’s largest privately-held cloud
infrastructure company
Create an accountGet started with
world’s largest privately-held cloud
infrastructure company